Havemeyer Place LP Makes New $1.92 Million Investment in Guardant Health, Inc. $GH

Havemeyer Place LP bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 18,838 shares of the company’s stock, valued at approximately $1,924,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health during the fourth quarter worth $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $35,000. Finally, Parallel Advisors LLC raised its holdings in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on GH shares. Citigroup increased their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Barclays increased their target price on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. The Goldman Sachs Group started coverage on shares of Guardant Health in a report on Friday. They set a “buy” rating and a $165.00 target price on the stock. Robert W. Baird started coverage on shares of Guardant Health in a report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. Finally, Wells Fargo & Company increased their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Guardant Health currently has an average rating of “Buy” and a consensus target price of $137.80.

Guardant Health Stock Down 5.6%

GH stock opened at $125.61 on Friday. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $134.28. The firm’s 50-day simple moving average is $99.39 and its 200 day simple moving average is $101.08. The stock has a market cap of $16.66 billion, a PE ratio of -37.05 and a beta of 1.61.

Insiders Place Their Bets

In related news, insider John G. Saia sold 10,000 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $125.08, for a total value of $1,250,800.00. Following the sale, the insider owned 35,950 shares of the company’s stock, valued at $4,496,626. This trade represents a 21.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the sale, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. This trade represents a 47.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 350,238 shares of company stock worth $38,538,372. 5.60% of the stock is owned by company insiders.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.